Plain-English translation of NCT03394365 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called for people who have developed a virus-related cancer called post-transplant lymphoproliferative disease (PTLD) after receiving either a solid organ transplant (kidney, liver, heart, lung, pancreas, or small bowel) or a blood stem cell transplant. The medication is made from immune cells that are specially matched to each patient and designed to fight the virus causing the cancer. This trial is for people whose disease did not improve after receiving standard treatments.
People who receive organ or stem cell transplants are at risk of developing this virus-related cancer because the medications they take to prevent transplant rejection also weaken their immune system. Standard treatments don't work for everyone, leaving some patients without good options. This trial is testing whether this new cell-based treatment can help patients whose disease has resisted standard medications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive intravenous infusions of the specialized cell treatment on days 1, 8, and 15 of each 5-week cycle. You will be monitored closely during this time and will have imaging scans to check how the cancer is responding. Treatment continues for as long as it is helping and you are tolerating it well, or until your doctor and you decide to stop. The study includes follow-up visits lasting up to 5 years to track your health and disease status after treatment ends.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States